Geranylgeranyl pyrophosphate (GGPP)

Geranylgeranyl pyrophosphate (GGPP) is a vital 20-carbon isoprenoid intermediate produced within the mevalonate pathway, serving as a critical branch point for the synthesis of various terpenes and the post-translational modification of proteins (PubChem, CID 5280458). Its primary biological function is to act as a substrate for geranylgeranyltransferases, which covalently attach the geranylgeranyl moiety to the C-terminus of small GTPases such as Rho, Rac, and Cdc42 (PubMed: 11162660). This process, known as geranylgeranylation, is essential for the membrane localization and functional activation of these signaling proteins, which regulate the actin cytoskeleton, cell polarity, and vesicular trafficking (PubMed: 16182142). In clinical practice, GGPP levels are indirectly modulated by several major drug classes, including statins and nitrogen-containing bisphosphonates, which deplete the GGPP pool to exert anti-inflammatory, anti-resorptive, or anti-tumor effects (PubMed: 22003301). Furthermore, the development of direct geranylgeranyltransferase inhibitors (GGTIs) represents a more targeted approach to disrupting Rho-dependent oncogenic signaling in various cancers (PubMed: 25611105). Consequently, GGPP acts as a central metabolic effector whose availability determines the activation state of numerous essential cellular pathways involved in bone health, cardiovascular function, and oncology.

Other names

Geranylgeranyl diphosphateGGdPh(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl phosphono hydrogen phosphateall-trans-Geranylgeranyl diphosphate

Depletion of the intracellular GGPP pool through inhibition of upstream mevalonate pathway enzymes (HMG-CoA reductase or Farnesyl pyrophosphate synthase) or competitive inhibition of the enzymes (Geranylgeranyltransferases) that utilize GGPP as a substrate.